Boehringer Ingelheim Initiates Long-term Study of Nerandomilast in Pulmonary Fibrosis Patients
A follow-up study is underway to evaluate the long-term tolerance and efficacy of nerandomilast in patients with pulmonary fibrosis.
Indication
Clinical and regulatory intelligence for Pulmonary Fibrosis with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.